Journal of Cellular and Molecular Medicine

Volume 18, Issue 10 pp. 1913-1926

Review Article

Open Access

MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways

Shi-Yun Cui

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Shi-Yun Cui and Rui Wang should be regarded as joint first authors for their equal contributions.Search for more papers by this author

Rui Wang,

Rui Wang

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Shi-Yun Cui and Rui Wang should be regarded as joint first authors for their equal contributions.Search for more papers by this author

Long-Bang Chen,

Corresponding Author

Long-Bang Chen

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Correspondence to: Prof. Long-Bang CHEN, Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, 315 Zhongshan East Road, Nanjing, Jiangsu 210002, China.

Tel.: +86-25-80860072

Fax: +86-25-80860072

E-mail: [email protected]

Search for more papers by this author

Shi-Yun Cui,

Shi-Yun Cui

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Shi-Yun Cui and Rui Wang should be regarded as joint first authors for their equal contributions.Search for more papers by this author

Rui Wang,

Rui Wang

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Shi-Yun Cui and Rui Wang should be regarded as joint first authors for their equal contributions.Search for more papers by this author

Long-Bang Chen,

Corresponding Author

Long-Bang Chen

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

Correspondence to: Prof. Long-Bang CHEN, Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, 315 Zhongshan East Road, Nanjing, Jiangsu 210002, China.

Tel.: +86-25-80860072

Fax: +86-25-80860072

E-mail: [email protected]

Search for more papers by this author

First published: 15 August 2014

https://doi.org/10.1111/jcmm.12358

Citations: 109

Share a link

Email
Wechat
Bluesky

Abstract

MicroRNAs are endogenous, small (18–25 nucleotides) non-coding RNAs, which regulate genes expression by directly binding to the 3′-untranslated regions of the target messenger RNAs. Emerging evidence shows that alteration of microRNAs is involved in cancer development. MicroRNA-145 is commonly down-regulated in many types of cancer, regulating various cellular processes, such as the cell cycle, proliferation, apoptosis and invasion, by targeting multiple oncogenes. This review aims to summarize the recent published literature on the role of microRNA-145 in regulating tumourigenesis and progression, and explore its potential for cancer diagnosis, prognosis and treatment.

● Introduction

● miR-145 biogenesis

● Down-regulation of miR-145

● The functions and pathways involving miR-145 targets

– MiR-145 in tumour growth inhibition

– MiR-145 in cancer invasion and metastasis

– MiR-145 in the differentiation of cancer stem cells

– MiR-145 in angiogenesis

– MiR-145 and cancer-associated virus

● MiR-145 in cancer diagnosis and prognosis

● MiR-145 in cancer therapy

● Conclusions and future directions

Introduction

For a long time, protein-coding genes have been considered the principal effectors and regulators of tumourigenesis. However, this concept has been revised recently. Non-coding RNAs have emerged as active modulators of the protein-coding gene function. Identification of non-coding RNA-based epigenetic regulatory networks has opened up an entirely new area of cancer research.

Among these, microRNAs (miRNAs) are the most-studied non-coding RNAs. They are short, 18–25 nucleotide, non-coding RNAs, which bind to target messenger RNAs (mRNAs), usually in their 3′-untranslated regions (UTR), and inhibit their expression by either inducing their degradation or repressing their translation. Since their discovery in 1993 1, 2, over 2500 miRNAs have been identified in the human genome, which are thought to regulate more than 30% of the protein-coding genes. Thus, they have emerged as integral components of nearly every biological process, including cell proliferation, migration, differentiation, apoptosis and angiogenesis 3. Recent evidence has shown that altered expressions of miRNAs are associated with carcinogenesis and development of various cancers 4. By regulating hundreds to thousands of potential target genes, miRNAs form a novel layer of the complicated regulatory network in cells. Thus, disorder of miRNA expression can lead to pathological changes in cells, ultimately contributing to the development of cancers.

MiR-145 was first predicted based on its homology to a verified miRNA from mouse 5, and was subsequently verified in humans, with significantly reduced levels in colorectal cancer 6. Slightly over half (52.5%) of miRNA genes are located in cancer-associated regions or fragile sites in the genome 7. Consistently, miR-145 is located on chromosome 5 (5q32-33), a well-known fragile site in the human genome 8, and is suggested to be co-transcribed with miR-143 9. Down-regulation of miR-145 has been observed in many types of cancers, suggesting that it may serve as a tumour suppressor. So far, miR-145 has been shown to be involved in regulating various cellular processes, such as the cell cycle, proliferation, apoptosis and invasion, by targeting multiple oncogenes. Moreover, reduced expression of miR-145 is associated with a worse prognosis for many cancers, indicating that it may serve as a potential cancer biomarker and an attractive target for cancer therapy. This review aims to summarize recent research on the physiology and pathological functions of miR-145 and its implications for clinical therapy.

MiR-145 Biogenesis

A unique biogenesis pathway produces miRNAs. RNA pol II transcribes most miRNAs from introns of protein-coding genes as long primary transcripts (pri-miRNAs) with a 5′ m⁷G cap and a 3′ poly-A tail. After transcription, pri-miRNAs undergo at least three steps before becoming the mature single-stranded form.

The pri-miRNA is cleaved into a stem-loop structure containing 60–70-nt (precursor) pre-miRNAs by the nuclear microprocessor complex, which comprises the RNase III enzyme Drosha (RNASEN), the DGCR8 (DiGeorge critical region 8), a double-stranded RNA binding protein and multiple RNA-associated proteins such as the DEAD-box RNA helicases p68 and p72 10. P68 and p72 are required for the maturation of miR-145, but not for all miRNAs 11. They enhance pre-miRNA processing by unwinding double-stranded stem loop-containing pre-miRNAs. After nuclear processing, the pre-miRNA is exported into the cytoplasm by RAN-GTPase/Exportin5 (Expo5) for further processing 12. Another RNase type III protein, Dicer, together with its partner TAR (HIV) RNA binding protein (TRBP), removes the loop region from the pre-miRNA and cleaves it into a ~22-nt double-stranded RNA product containing two forms of mature miRNAs that can be cleaved from either the 5′ or 3′ arm extending out from the stem loop of the pre-miRNA 13-16. For example, mature miR-145 has two different forms, 5p and 3p, according to which side of the strand they were derived from (Fig. 1).

Details are in the caption following the image — **Figure 1**
Open in figure viewer PowerPoint

The structure of pre-miR-145. Drosha cuts Pri-miR-145 the stem-loop structural pre-miR-145, and then Dicer removes the loop region from pre-miRNA, leaving the mature sequence. Mature miR-145 has two different forms, namely 5p and 3p, according to which side of the strand they are derived from.

The guide strand or mature miRNA is bound by Argonaute (Ago) to form a miRNA-induced silencing complex (miRISC), which targets the 3′-UTR of the complementary mRNAs for regulation, whereas the passenger strand is usually degraded 17. The specificity of miRNA targeting is defined by how complementary are the ‘seed’ sequence (positions 2 to 8 from the 5′end of the miRNA) and the ‘seed-match’ sequence (generally in the 3′ UTR of the target mRNA). A perfect match between miRNAs and mRNA sequences promotes the degradation of mRNAs by Ago1/2, while an imperfect match usually leads to translational repression 18. The imperfect nature of the miRNA:mRNA interaction means that a single miRNA can potentially target tens to hundreds of mRNAs.

Down-regulation of miR-145 in cancer

Reduced expression of miR-145 has been reported in many types of cancer. The first report, from Michael et al., observed low expression of miR-145 in colonic adenocarcinoma compared with mucosa 6. This result was confirmed by further research in different cancer cell lines, including both solid and blood malignancies (Table 1). This evidence indicated widespread deregulation of miR-145 levels in various cancers.

Table 1. Down-expression of miR-145 in cancers

Cancer types	Technique for detection	References
Lung	Microarray, qRT-PCR, in situ hybridization	19
Lung	Microarray, qRT-PCR	20
Breast	Microarray, qRT-PCR	21, 22
	Microarray, northern blot	23
	Microarray, qRT-PCR, in situ hybridization	24
Ovary	Microarray, northern blot	25, 26
Ovary	Microarray, qRT-PCR	27
Prostate	Microarray, qRT-PCR	28-31
Colon	Microarray, qRT-PCR	6, 32-37
Liver	Microarray	38
	Microarray, qRT-PCR	39-41
	qRT-PCR	42
Biliary tract	qRT-PCR	43
Larynx	Microarray, qRT-PCR	44
Oesophagus	Microarray, qRT-PCR	45-48
Pancreas	qRT-PCR	49
Oral	Microarray, qRT-PCR	50, 51
Bladder	Microarray, qRT-PCR	52-55
Bladder	qRT-PCR	56, 57
Nasopharynx	Microarray, qRT-PCR	58
Glioma	Microarray, qRT-PCR	59
Cutaneous squamous cell carcinoma	Microarray, qRT-PCR	60
Basal cell carcinoma	Microarray, qRT-PCR	61
Liposarcoma	Microarray, qRT-PCR	62
B-cell malignancies	qRT-PCR	63

However, the mechanisms responsible for its down-regulation are largely unknown. Gene expression regulation is a multilayered network, where transcription is a major regulatory step for the biosynthesis of miRNAs. A couple of transcriptional factors have been identified that modulate the expression of miR-145, and an epigenetic mechanism also plays an important role in the silencing of miR-145. After transcription, pri-miR-145 undergoes several processing steps before its maturation, where some factors also play essential roles at the post-transcriptional level (Fig. 2).

p53 is a master tumour suppressor that controls diverse cellular pathways. Recent evidence indicated that some miRNAs are also regulated by p53, such as miR-34, miR-192/215, miR-107 and miR-145 64, 65. Sachdeva et al. found that p53 could increase miR-145 expression by directly binding to the p53 response elements-2 (p53RE-2) in the miR-145 promoter, which was possibly the mechanism of p53-mediated repression of c-Myc 66. Low miR-145 expression was demonstrated in both laser capture microdissected prostate tissues and 47 cancer cell lines, coupled with p53 mutations 67. Glucocorticoid-induced human papillomavirus oncoprotein E6 (HPV-E6) activation suppressed p53 and miR-145 expression in cervical cancer 68. The tumour-suppressive effect of miR-145 is dependent on p53 activation in some tumours 69, 70. Furthermore, Suzuki et al. discovered that p53 could facilitate Drosha-mediated pri-miR-145 processing through an association with the DEAD-box RNA helicase p68 (also known as DDX5), a key component of the Drosha complex, indicating post-transcriptional regulation also plays an important role in the modulation of miR-145 expression by p53 71. Interestingly, there seems to be positive feedback regulation between miR-145 and p53, partially by impairing the murine double minute 2 (MDM2)-p53 feedback loop 70, 72. This could partially explain why miR-145 is frequently down-regulated in p53-mutated cancers.

The Kras gene mutation is commonly found in many malignancies, and can stimulate a number of downstream effectors, including the mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K) pathways, ultimately promoting cellular proliferation, survival and motility 73. Kent et al. showed that Kras signalling led to repression of the miR-143/145 cluster by activating Ras-responsive element-binding protein 1 (RREB1) in pancreatic cancers. In turn, miR-143 and miR-145 targeted KRAS and RREB1, establishing a feedback circuit of Ras signalling 74. The same results were also obtained in colorectal cancers 75. Consistent with this, there is an inverse correlation between KRAS and the miR-143/145 cluster in colorectal cancer 76.

However, the reason for the low expression of miR-145 in tumours with wild-type p53 is unclear, implying that factor(s) other than p53 are involved in miR-145 regulation. In addition to p53, other transcription factors participate in the regulation of miR-145, including CCAAT/enhancer-binding protein-beta (C/EBP-β), beta-catenin/T cell factor 4 (TCF4) and forkhead transcription factors of the O class 1 and 3 (FoxO1 and FoxO3) 77-79. In addition, DNA methylation in the upstream sequence of miR-145 contributes to the down-regulation of miR-145 in prostate cancer, and, importantly, interferes with the binding of p53 to the p53 response element in the upstream region of miR-145 67.

Post-transcriptional regulation is also critical for miR-145 expression. Apart from p53, Breast cancer 1 (BRCA1) recognizes the root of the stem-loop structure of pri-miR-145, directly associates with Drosha and DDX5 of the Drosha complex, and interacts with Smad3, p53, and DHX9 RNA helicase, promoting miR-145 processing 80. Similarly, the p38 MAPK-MK2 signalling pathway promotes miR-145 biogenesis by facilitating the nuclear localization of DDX5 81. Conversely, BCDIN3D is a methyltransferase that modifies the 5′-monophosphate end of miRNAs, including pre-miR-145, which affects their recognition by Dicer. BCDIN3D depletion reduced the level of pre-miR-145 and increased the level of mature miR-145 in breast cancer cells 82. DEAD-box RNA helicase 6 (DDX6) preferentially increases the instability of the host gene product of miR-145 (NCR143/145) by promoting the assembly of processing bodies (P-bodies), thus negatively regulating miR-145 expression at the post-transcriptional level 83. Doublecortin-like kinase 1 (DCLK1) post-transcriptionally regulates miR-145 in pancreatic cancer; however, the mechanism is unclear 84.

The functions and pathways involving miR-145 targets

To date, numerous oncogenic genes have been confirmed as targets for miR-145, which cover multiple biological pathways, including proliferation, invasion, differentiation, angiogenesis and cancer-related viruses, supporting the proposed tumour-suppressor role of miR-145 in cancers (Table 2). For example, miR-145 could suppress cancer cell proliferation by targeting growth factor-related genes such as IRS-1, IGF-IR or epidermal growth factor receptor (EGFR) 85-87. Moreover, inducing cell apoptosis and cell cycle arrest by inhibiting DFF45, CBFB, CLINT1, PPP3CA or c-Myc also contributes to miR-145-mediated tumour growth suppression 66, 88, 89. Direct regulation of some oncogenes involved in cancer cell invasion and metastasis, like MUC1, FSCN1, NEDD9 and SOX9, by miR-145 has been identified in many cancers 90-93. In addition, there is evidence that miR-145 has an important role in regulating cell differentiation by targeting core reprogramming factors, including OCT4, SOX2 and KLF4 94, 95. Meanwhile, miR-145 could retard angiogenesis process by targeting VEGF, hypoxia-inducible factor 1α (HIF-1α) or N-RAS 96-98. What is more, some cancer-related virus genes, such as infected-cell polypeptide 4 (ICP4), have been validated as targets for miR-145 99. By regulating these target genes, miR-145 exerts a potent tumour-suppressive effect. However, the number of target genes is still growing, indicating a complicated regulatory network for miR-145.

Table 2. The functions and involved pathways of miR-145 targets

Target gene	Involved pathway	Cancer types	References
IRS-1, IGF-IR	Proliferation	Colon cancer, hepatocarcinoma	85, 87-89, 164
EGFR, NUDT1	Proliferation	NSCLC	90
ILK	Proliferation	Bladder cancer	93
DFF45	Apoptosis	Colon cancer	94
CBFB, PPP3CA and CLINT1	Apoptosis	Bladder cancer	95
TNFSF10	Apoptosis	Prostate cancer	97
SOCS7	Apoptosis	Bladder cancer	98
c-Myc	Proliferation, apoptosis, invasion	Colon cancer, NSCLC, ovarian cancer, breast cancer, oesophageal and oral squamous cell carcinoma	66, 99, 101-104
FLI1, EWS-FLI1, Ets1(ERG),	Proliferation, apoptosis, invasion	Colon cancer, prostate cancer, gastric cancer, Ewing's sarcoma	106-108, 110
RTKN	Proliferation	Breast cancer	112
YES, STAT1	Proliferation	Colon cancer	113
HDAC2	Proliferation	Hepatocarcinoma	114
PAI-1	Unknown	Bladder cancer	115
MUC1	Invasion	Breast cancer, ovarian cancer	121-123
FSCN1	Invasion	Bladder cancer, oesophageal squamous cell carcinoma, prostate cancer, breast cancer, melanoma	124-130
JAM-A	Invasion	Breast cancer	129
SWAP70	Invasion	Prostate cancer	131
HEF1/NEDD9	Invasion	Glioblastoma, prostate cancer, renal cell carcinoma	134-136
N-cadherin	EMT, invasion	Gastric cancer	137
ADD3	Invasion	Glioma	138
ADAM17	Proliferation, invasion	Renal cell carcinoma	140, 141
SOX9	Proliferation, invasion, CSCs	Glioma, head and neck cancer	138, 142
CTGF	Invasion	Glioma	143
Catenin delta-1	Proliferation, cell cycle, invasion	Colon cancer	144
PAK4	Proliferation, invasion	Colon cancer	145
OCT4	Differentiation and CSCs	Human embryonic stem cells, hepatocarcinoma, breast cancer, NSCLC, endometrial adenocarcinoma, skin keratinocyte	41, 93, 95, 153, 155-157, 167
SOX2	Differentiation and CSCs	Human embryonic stem cells, glioblastoma	153, 154
KLF4	Differentiation and CSCs	Human embryonic stem cells	153
VEGF	Angiogensis, invasion	Osteosarcoma	161
p70S6K1	Proliferation, angiogenesis, invasion	Colon cancer, ovarian cancer	123, 162
N-RAS	Angiogenesis	Breast cancer, colorectal cancer	163, 164
ICP4	Virus	Prostate cancer	166

MiR-145 in tumour growth inhibition

The tumour-suppressive function of miR-145 is related to its regulation of cell proliferation. The first report describing tumour growth inhibition by miR-145 was from a study in colon cancer cells, where miR-145 suppressed tumour growth by targeting insulin receptor substrate-1 (IRS-1) 85. MiR-145-mediated tumour growth inhibition was also found in cervical cancer and lung adenocarcinomas 19, 100. IRS1 is also involved in miR-145′s ability to suppress cell proliferation, anchorage-independent growth and cell motility in gastric cancer and hepatocellular carcinoma 101. Interestingly, the insulin-like growth factor I receptor (IGF-IR) is also a predominant target of miR-145, by which miR-145 suppresses the tumour growth of colorectal cancer and hepatocellular carcinoma, suggesting that the IGR/IRS1 pathway plays an important role in miR-145-mediated anti-proliferative function 86, 102.

Furthermore, Cho et al. described strong suppression of tumour growth by miR-145 in lung adenocarcinoma patients with an EGFR mutation 20. They further stated that EGFR and nucleoside diphosphate-linked moiety X-type motif 1 (NUDT1) were regulated by miR-145 87. Similarly, forced expression of miR-145 could suppress EGF-induced growth in vitro and tumour xenograft growth in vivo, suggesting that the EGFR pathway might be involved in the tumour-suppressive effect of miR-145 103. In addition, EGFR-independent activity of the PI3K/Akt or Ras/ERK pathway contributes to EGFR-targeted agents-resistance in non-small cell lung cancer (NSCLC) cell lines. MiR-145 could enhance the cytotoxicity of gefitinib by reducing the activation of Akt rather than ERK 104. Further research indicated that miR-145 indirectly regulates the Akt pathway by directly targeting Integrin-Linked Kinase (ILK), and co-treatment with miR-143 and miR-145 synergistically inhibited cell growth in bladder cancer cells 105.

MiR-145 induces caspase-3-dependent apoptosis in colon cancer by targeting DNA fragmentation factor 45 (DFF45), which is the substrate of caspase-3 and whose cleavage by caspase-3 during apoptosis releases DFF40, which degrades chromosomal DNA into nucleosomal fragments 88. Ostenfeld et al. reported that miR-145 induced caspase-dependent and -independent cell death in human urothelial cancer cells by targeting Clathrin Interactor 1 (CLINT1), core-binding factor β subunit (CBFB) and protein phosphatase 3 catalytic subunit α isoform (PPP3CA) 89. However, two other reports also suggested a role of miR-145 in Tumour Necrosis Factor-related Apoptosis-Inducing Ligand (TRAIL)-induced apoptotic cell death 106, 107. In bladder cancer, miR-145 induces interferon (IFN)-beta-mediated apoptosis by targeting the suppressor of cytokine signalling 7 (socs7) 108. Moreover, over-expression of miR-145 increased the cleaved-PARP expression and induced apoptosis in breast cancer cells, by repression of oestrogen receptor-α (ER-α) and up-regulation of the TP53 transcriptional targets, such as p53 up-regulated modulator of apoptosis (PUMA) and P21, indicating that miR-145 activates the TP53 pathway and suppresses ER-α 70.

Sachdeva et al. revealed that miR-145 causes cell cycle arrest at G0-G1 phase and a decrease in S-phase, partially through silencing the expression of c-Myc 66. Consistent with these results, the miR-145-induced G1/S-phase arrest is mediated by c-Myc in NSCLC, with downstream regulation of CDK4 109. C-Myc, along with the DNA-binding protein Miz-1, binds to the p21(Cip1) promoter and blocks its transcription induction by p53 and other activators, thus preventing p53-mediated apoptosis 110. Therefore, forced expression of miR-145 could restore p53-induced cell cycle arrest, which was likely to be caused, in part, by silencing c-Myc 66. Moreover, the regulation of c-Myc by miR-145 has been associated with proliferation, apoptosis and metastasis in various cancers, including colon cancer, NSCLC, ovarian cancer, breast cancer, oesophageal and oral squamous cell carcinoma 66, 109, 111-114, highlighting the potent tumour-suppressive effect of the miR-145/c-Myc pathway.

MiR-145 regulates certain oncogenic transcription factors to suppress cell growth. For example, E-26 (ETS) transcriptional factors are well-known proto-oncogenes with mitogenic and transforming activity 115. Some members of the ETS family, such as the Friend leukaemia virus integration 1 (FLI1) and the v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), were identified as targets of miR-145, and are involved in miR-145-mediated apoptosis and repression of cell proliferation in colon and prostate cancer, respectively 116, 117. Moreover, miR-145 regulates the expression of Ets1 and its downstream genes, matrix metalloproteinase-1 (MMP-1) and -9, thus inhibiting the invasion, metastasis and angiogenesis of gastric cancer cells 118. Interestingly, EWS-FLI1 is a chromosome translocation-derived chimeric transcription factor that is the major driver of the proliferation of Ewing's sarcoma 119. The EWS-FLI1 gene shares the same 3′-UTR with the FLI1 gene; therefore, its relationship with miR-145 has been explored in Ewing's sarcoma. It transpired that there is feedback regulation between EWS-FLI1 and miR-145 in Ewing's sarcoma growth regulation 120. MicroRNA/mRNA profiling in ovarian cancer suggested a negative correlation between miR-145 and a transcriptional factor, E2F3, but it is not clear whether there is a direct regulation 121.

In addition, there are multiple oncogenic genes that have been identified as targets of miR-145, including RTKN, YES, STAT1, HDAC2 and PAI-1 122-125, contributing to its tumour growth-suppressive effect.

MiR-145 in cancer invasion and metastasis

MiR-145 was observed to be differentially expressed in node-negative patients or node-positive gastric cancer patients 126. Similarly, effusion samples contain lower miR-145 levels than primary ovarian cancers, suggesting a role of miR-145 in cancer progression 27. MiR-145 is also a biomarker in the transition from localized prostate adenocarcinoma to metastasis 127. Restoration of miR-145 expression could inhibit the migration and invasion ability of cancer cells 40, 128. These reports provide a new insight into miR-145-mediated suppression of invasion and metastasis. Mucin 1 (MUC1) is co-expressed with β-catenin at the invasion front of colorectal carcinoma, and is associated with progression of disease and poor prognosis 129. In addition, MUC1 interacts with β-catenin, promoting invasion of breast cancer 130. Therefore, it is considered as an important metastasis gene. MiR-145 suppresses cell invasion and lung metastasis of breast cancer in vitro and in vivo, and this effect is, in part, attributed to silencing of MUC1 90, 131, 132. Recent research also described the relationship between miR-145 and some adhesion or cytoskeleton molecules. For example, Fascin homologue 1 (FSCN1), an actin-binding protein, is a candidate target gene of miR-145. MiR-145 participates in the modulation of proliferation and invasion by targeting FSCN1 in various cancers, including bladder cancer, oesophageal squamous cell carcinoma, prostate cancer, melanoma cells and breast cancer cells 91, 133-138. Notably, a more cortical actin distribution, reduced actin stress fibres and filopodia formation, and nuclear rotation were observed in miR-145-transfected breast cancer cells by immunofluorescence microscopy. Their effects were partially attributed to the miR-145-dependent regulation of Junctional Adhesion Molecule A (JAM-A) and FSCN1, which contribute to the cytoskeletal rearrangements and cell motility 137. Similar to FSCN1, another actin-binding protein, the SWAP switching B-cell complex 70 kD subunit (SWAP70), was confirmed as a target of miR-145, which is associated with miR-145's modulation of cell migration and invasion in prostate cancer 139. Human enhancer of filamentation 1(HEF1/CAS-L/NEDD9) is a non-catalytic scaffolding protein that interacts with FAK and Src to create binding sites for effector proteins, such as Rac and the Cas-Crk complex. It has been proposed to be involved in cancer invasion and epithelial-mesenchymal transition (EMT) 140, 141. Recent research demonstrated that NEDD9 promotes the invasiveness of glioblastoma under the regulation of miR-145, and low expression of miR-145 in glioblastoma was associated with a more aggressive phenotype 92. NEDD9 also mediated the function of miR-145 in regulating EMT, migration and invasion in prostate cancer and renal cell carcinoma 142, 143. MiR-145 also targets N-cadherin, a calcium-dependent cell adhesion molecule associated with an increased invasive potential, suppressing invasion and metastasis, rather than inhibiting cell proliferation in gastric cancer 144. Besides direct regulation, the impact of miR-145 on E-cadherin and N-cadherin expression in glioma is partially caused by its regulation of Adducin 3 (ADD3), a cell adhesion-associated molecule 145. Another target gene, Metalloproteinase 17 (ADAM17), is an important member of the ADAM family involved in cancer invasion 146 that plays an important role in the effects of miR-145 on proliferation and migration in renal cancer and glioma cells 147, 148. SRY (sex determining region Y) box 9 (SOX9), a positive transcription factor of ADAM17, is also a target of miR-145 and participates in the regulation of tumour-initiating cell and IL-6-mediated paracrine effects in head and neck cancer 93. In addition, miR-145 regulates glioma cell migration by targeting connective tissue growth factor (CTGF), a member of the CCN family, which decreases the expression and phosphorylation of FAK and the expression of secreted protein acidic and rich in cysteine, two important cell migration-relative pathways 149. Moreover, miR-145 directly targets catenin δ-1 and impairs nuclear translocation of β-catenin by disturbing the nuclear import of p21-activated kinase 4 (PAK4), leading to the down-regulation of downstream target genes c-Myc and CyclinD1, which contribute to the attenuation of cell migration and invasion activities in colon cancer 150. PAK4 was also proposed as a direct target of miR-145 151. The above evidence strongly supports the anti-metastatic role of miR-145 in cancer cells.

By contrast, several reports describe the oncogenic effect of miR-145. Although miR-145 and miR-143 are both down-regulated in colorectal cancer samples compared with normal tissues, miR-145 promoted proliferation and morphology in a metastatic colorectal cancer cell line while miR-143 did the contrary. Bioinformatic analysis found that miR-145 targets are differentially expressed between metastatic and non-metastatic isogenic cell line models 152. MiR-145, along with miR-143, was over-expressed in a serial selected invasive glioblastoma cell line, and knocking down both of them demonstrated a synergistic anti-invasive effect 153. Therefore, the role of miR-145 in metastasis may be tissue-specific, and targeting miR-145 in metastatic cancers requires discreet consideration.

MiR-145 in the differentiation of cancer stem cells

Cancer stem cells (CSCs) are a minority population of cells within a tumour, and are characterized by self-renewal and high tumourigenic capacity. Recent evidence suggests that CSCs might be formed during the process of EMT, and play important roles in development, recurrence, metastasis and drug resistance of cancer 154, 155. Embryonic pluripotent stem cells share a similar capacity for self-renewal and transformation into differentiated cells with CSCs, which are maintained by a group of transcription factors in both mice and human, including OCT4, SOX2 and Kruppel-like factor 4 (KLF4) 156-158. Xu et al. revealed a direct link between miR-145 and these core reprogramming factors 94. Further research confirmed the reciprocal negative regulation of miR-145 and OCT4 and SOX2 94, 159. Given the role of miR-145 in silencing pluripotency during embryonic stem cell differentiation, it is not surprising that miR-145 also inhibits the proliferation of CSCs and induces differentiation, contributing to suppression of tumour growth, migration and EMT 41, 95, 160-162. Moreover, forced expression of miR-145 suppressed tumour sphere formation and expression of CSC markers and ‘stemness’ factors, including CD133, CD44, Oct4, c-Myc and Klf4 in prostate cancer cells, and inhibited bone invasion and tumourigenesis of prostate cancer in vivo 163.

MiR-145 in angiogenesis

Angiogenesis is a process by which new blood vessels sprout from existing vasculature. It is vital for tumour growth and metastasis, because cancer cells cannot grow beyond 2 mm³ without vascular support 164. MiR-145 exhibits tumour-suppressive functions by modulating angiogenesis. VEGF, one of the strongest angiogenic factors, is a direct target of miR-145, regulating the invasion and metastasis of osteosarcoma cells, which implies a role of miR-145 in modulating tumour angiogenesis 96. In addition, miR-145 decreases HIF-1α expression, a major transcriptional regulator of VEGF in response to hypoxia, as well as decreasing VEGF expression by targeting p70S6K1 in colorectal cancer, leading to the inhibition of tumour growth and angiogenesis 97. In addition to VEGF, N-RAS was identified as a target of miR-145, which plays a pivotal role in its anti-angiogenic effect in breast cancer 98. Further research showed that miR-145 inhibits N-RAS and IRS1 expression to suppress AKT and ERK1/2 activation and VEGF expression in colorectal cancer 165.

MiR-145 and cancer-associated virus

Surprisingly, miR-145 plays an important role in interfering with the cancer-associated viruses-mediated tumourigenesis process. In head and neck squamous cell carcinoma (HNSCC), the HPV-positive (HPV+) samples had a different miRNA profile from the HPV-negative (HPV−) samples, which was more similar to the miRNA profile of cervical squamous cell carcinoma than HPV-HNSCC. Among the HPV core miRNAs was the miR-143/145 cluster, suggesting miR-145 as a potential HPV-specific tumour marker 166. In addition, miR-145 could target a herpes simplex virus-1 essential viral gene, ICP4, to create CMV-ICP4-143T and CMV-ICP4-145T amplicon viruses, leading to restriction of viral replication and oncolysis of prostate cancer cells while sparing normal tissues, both in vitro and in vivo 99.

MiR-145 in cancer diagnosis and prognosis

Specific miRNAs have been found to be differentially expressed in the majority of tumour cases; therefore, miRNA expression patterns are capable of distinguishing between malignant and non-malignant tissue. MiR-145 is differentially expressed in breast cancers and normal breast tissues, and its down-regulation is closely associated with invasive breast cancer pathobiological features 23. A noticeable decrease in miR-145 expression was observed in hyperplastic, probable pre-neoplastic, ducts present in normal breast tissues compared with normal ducts, as well as in carcinoma in situ and invasive carcinoma, compared with normal tissues 24. In another study, miR-145 was identified as one of the eight basal cell type-specific miRNAs in breast cancer 168. In addition, Wach et al. demonstrated that miR-145 was the best discriminating miRNA that could correctly classify 71% of prostate cancer tissue samples and, when combined with miR-375 and miR-143, the correct classification rate of miR-145 reached almost 78%, suggesting that miR-145 could serve as valuable biomarker for the diagnosis of prostate cancer 169. Another independent study obtained an area under the curve (AUC) of 0.74 for the ability of miR-145 expression to discriminate between prostate cancer and non-tumour tissues 30. MiR-145 can also distinguish between subtypes of certain tumours, such as intestinal-type and diffuse-type gastric cancers 170; primary central nervous system lymphomas and nodal diffuse large B-cell lymphomas 171; clear-cell renal cell carcinoma and papillary renal cell carcinoma 172; and different subtypes of liposarcoma 62.

Furthermore, as a non-invasive, blood-based diagnostic tool, cell-free miRNAs have received much interest in recent years. Serum miR-145 has a distinct level in cancer patients compared with healthy ones, suggesting that detection of serum miR-145 has potential as a novel method for early cancer diagnosis 173, 174. Moreover, recent evidence has revealed that a combination of circulating miRNAs biomarkers show better sensitivity and specificity for cancer diagnosis. For example, in two independent studies, a combination of plasma markers miR-145 and miR-451, or a combination of miR-145, miR-155 and miR-382, were suggested to increase the sensitivity and specificity for discriminating breast cancer from healthy controls 175, 176. Likewise, circulating miR-145 combined with three other circulating miRNAs (miR-20a, miR-21 and miR-221) significantly identified aggressive prostate cancer patients, with an AUC of 0.824 177. Similarly, the combination of three plasma miRNAs (miR-21, miR-145 and miR-155) demonstrated strong potential as a diagnostic marker for early detection of lung cancer, with an AUC of 0.847 178. Moreover, cell-free miRNAs in other body excretions provide a novel approach for cancer diagnosis. The miR-145 level in urine was able to distinguish bladder cancer patients from non-cancer controls (77.8% sensitivity and 61.1% specificity for non-muscle invasive bladder cancer, AUC 0.729; and 84.1% and 61.1% for muscle invasive bladder cancer, respectively, AUC 0.790) and was significantly correlated with grade 179. Li et al. also explored the value of faecal miR-145 expression for colorectal cancer diagnosis 180.

On the other hand, many reports have shown that miRNAs, including miR-145, are associated with the clinical outcome of human cancer patients. Time to relapse (TTR) was significantly shorter for NSCLC patients with low miR-145 expression compared with those with high levels. Furthermore, the combination of low miR-145 with p53 mutations was an independent marker of shorter TTR 181. In a study of 527 stage I NSCLC patients, low expression of miR-145 was correlated with brain metastasis 182. Huang et al. determined that down-regulation of miR-145 was associated with advanced stage and lymph node metastasis in small cell carcinoma of cervix 183. In addition, miR-145 expression levels in colorectal cancer were associated with tumour stage, depth of invasion (pT category), lymph node status (pN category), development of distant metastases, grade of tumour differentiation, maximal tumour diameter, anatomical localization and serum carcinoembryonic antigen levels, suggesting its potential role as a prognostic marker of colorectal cancer 184. In addition, miR-145 expression is able to predict the response of cancer cells to certain antitumour agents. For example, rectal cancer patients with a low intratumoural post-therapeutic expression of miR-145 had a significantly worse response to neoadjuvant therapy with 5-FU and 50.4 Gy radiation compared with those with high expression, suggesting miR-145 could serve as a response-predicting and prognostic marker in the course of neoadjuvant-treated colorectal cancer 185. Likewise, a profile of five serum miRNAs (miR-20a, miR-130, miR-145, miR-216 and miR-372) was identified as a biomarker to predict the chemosensitivity of colorectal cancer 186. However, in a study of 98 primary colorectal specimens, along with the corresponding normal mucosa specimens, miR-145 down-regulation had no relationship with other clinicopathological features, except the cancer site 187. Results from another group also found no outcome or clinicopathological relevance of miR-145 in colorectal cancer patients 188.

MiR-145 in cancer therapy

The observation of decreased levels of tumour-suppressive miRNAs in cancers has led to the concept of miRNA replacement therapy. Recently, encouraging results have been achieved in several animal models 189-191. A systemic or local application of a polyethylenimine-mediated delivery of unmodified miR-145 in a mouse model of colon carcinoma obtained a 40% or 60% decrease in tumour growth, respectively, with concomitant repression in ERK5 and c-Myc protein levels compared with negative controls 192. Moreover, delivery of miR-145 mimics by mesenchymal stem cells significantly decreased the migration of glioma cells and the self-renewal of germline stem cells 193.

On the other hand, MiR-145 can influence the sensitivity of tumours to chemo- or radiation therapy, and a combination of miR-145 and chemo- or radiation therapy represents a novel antitumour strategy. Treatment with miR-145 inhibited gastric cancer cell growth and increased its sensitivity to 5-FU 194. Similarly, an adenoviral constructed miR-145 was injected into breast cancer orthotopic mouse models intratumourally, resulting in significant suppression of tumour growth. Furthermore, a treatment combining adenoviral miR-145 and 5-FU produced enhanced retardation of tumour growth, compared with treatment with either drug alone 112. In addition, miR-145 is able to enhance sensitivity to some molecular targeted drugs, including gefitinib and vemurafenib 104, 195. Ikemura et al. confirmed that MDR1 mRNA was a direct target of miR-145 196. However, further studies are still required to elucidate the mechanisms underlying the miR-145-mediated regulation of resistance to chemo- or radiotherapy.

Conclusions and future directions

In summary, much evidence indicates that miR-145 represents a potent tumour suppressor, and aberrant miR-145 expression is found commonly in different cancers. Its tumour-suppressive function can be attributed to its regulation of target genes involved in multiple pathways, including proliferation, invasion, angiogenesis and CSCs. MiR-145 is closely associated with many signalling pathways; therefore, the discovery of novel targets is still required to obtain a comprehensive knowledge of the biological roles of miR-145.

The close association between low expression of miR-145 and poor prognosis in cancer patients makes it a valuable prognostic biomarker. Moreover, its potential for cancer diagnosis has also been supported by many studies. More appealing is miR-145-based therapy. MiR-145 treatment can improve the sensitivity to chemotherapy agents in cancer cells, providing a new strategy for overcoming drug resistance. Furthermore, recent progress in drug-delivered systems provides a technical solution for the application of miRNA-based therapy to pre-clinical research. Currently, the application of specific miRNA mimics has demonstrated a great tumour-suppressive capacity in experimental tumour models, such as let-7 or miR-34 189-191. Research into miR-145-based therapy, however, is at an early stage, and effective delivery to the target tissues and drug safety remain challenges. Further investigation of miR-145 may lead to novel therapeutic strategies.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (No's. 30901440, 81172335, 81071806 and 81172106). The authors thank everyone at the Department of Medical Oncology for their generous help.

Conflicts of interest

The authors declare no conflicts of interest related to this article.

References

1Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–54.
10.1016/0092-8674(93)90529-Y
CAS PubMed Web of Science® Google Scholar
2Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75: 855–62.
10.1016/0092-8674(93)90530-4
CAS PubMed Web of Science® Google Scholar
3Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10: 704–14.
10.1038/nrg2634
CAS PubMed Web of Science® Google Scholar
4Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27: 5848–56.
10.1200/JCO.2009.24.0317
CAS PubMed Web of Science® Google Scholar
5Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12: 735–9.
10.1016/S0960-9822(02)00809-6
CAS PubMed Web of Science® Google Scholar
6Michael MZ, SM OC, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1: 882–91.
CAS PubMed Web of Science® Google Scholar
7Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004; 101: 2999–3004.
10.1073/pnas.0307323101
CAS PubMed Web of Science® Google Scholar
8Le Beau MM, Lemons RS, Espinosa R, et al. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood. 1989; 73: 647–50.
CAS PubMed Web of Science® Google Scholar
9Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009; 460: 705–10.
10.1038/nature08195
CAS PubMed Web of Science® Google Scholar
10Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004; 432: 235–40.
10.1038/nature03120
CAS PubMed Web of Science® Google Scholar
11Fukuda T, Yamagata K, Fujiyama S, et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol. 2007; 9: 604–11.
10.1038/ncb1577
CAS PubMed Web of Science® Google Scholar
12Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003; 17: 3011–6.
10.1101/gad.1158803
CAS PubMed Web of Science® Google Scholar
13Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001; 293: 834–8.
10.1126/science.1062961
CAS PubMed Web of Science® Google Scholar
14Ketting RF, Fischer SE, Bernstein E, et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001; 15: 2654–9.
10.1101/gad.927801
CAS PubMed Web of Science® Google Scholar
15Haase AD, Jaskiewicz L, Zhang H, et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep. 2005; 6: 961–7.
10.1038/sj.embor.7400509
CAS PubMed Web of Science® Google Scholar
16Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005; 436: 740–4.
10.1038/nature03868
CAS PubMed Web of Science® Google Scholar
17Cheloufi S, Dos Santos CO, Chong MM, et al. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010; 465: 584–9.
10.1038/nature09092
CAS PubMed Web of Science® Google Scholar
18Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215–33.
10.1016/j.cell.2009.01.002
CAS PubMed Web of Science® Google Scholar
19Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009; 15: 1177–83.
10.1158/1078-0432.CCR-08-1355
CAS PubMed Web of Science® Google Scholar
20Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009; 45: 2197–206.
10.1016/j.ejca.2009.04.039
CAS PubMed Web of Science® Google Scholar
21Lehmann U, Streichert T, Otto B, et al. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer. 2010; 10: 109.
10.1186/1471-2407-10-109
CAS PubMed Web of Science® Google Scholar
22Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011; 10: 507–17.
10.4161/cc.10.3.14754
CAS PubMed Web of Science® Google Scholar
23Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065–70.
10.1158/0008-5472.CAN-05-1783
CAS PubMed Web of Science® Google Scholar
24Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007; 67: 11612–20.
10.1158/0008-5472.CAN-07-5019
CAS PubMed Web of Science® Google Scholar
25Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67: 8699–707.
10.1158/0008-5472.CAN-07-1936
CAS PubMed Web of Science® Google Scholar
26Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14: 2690–5.
10.1158/1078-0432.CCR-07-1731
CAS PubMed Web of Science® Google Scholar
27Vaksman O, Stavnes HT, Kaern J, et al. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011; 15: 1593–602.
10.1111/j.1582-4934.2010.01148.x
CAS PubMed Web of Science® Google Scholar
28Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007; 67: 6130–5.
10.1158/0008-5472.CAN-07-0533
CAS PubMed Web of Science® Google Scholar
29Ozen M, Creighton CJ, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008; 27: 1788–93.
10.1038/sj.onc.1210809
CAS PubMed Web of Science® Google Scholar
30Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010; 126: 1166–76.
10.1002/ijc.24827
CAS PubMed Web of Science® Google Scholar
31Hart M, Nolte E, Wach S, et al. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep-sequencing. Mol Cancer Res. 2014; 12: 250–63.
10.1158/1541-7786.MCR-13-0230
CAS PubMed Web of Science® Google Scholar
32Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008; 68: 6416–24.
10.1158/0008-5472.CAN-07-6110
CAS PubMed Web of Science® Google Scholar
33Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006; 16: 845–50.
CAS PubMed Web of Science® Google Scholar
34Bandres E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006; 5: 29.
10.1186/1476-4598-5-29
CAS PubMed Web of Science® Google Scholar
35Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009; 34: 1069–75.
CAS PubMed Web of Science® Google Scholar
36Hamfjord J, Stangeland AM, Hughes T, et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS ONE. 2012; 7: e34150.
10.1371/journal.pone.0034150
CAS PubMed Web of Science® Google Scholar
37Tan YG, Zhang YF, Guo CJ, et al. Screening of differentially expressed microRNA in ulcerative colitis related colorectal cancer. Asian Pac J Trop Med. 2013; 6: 972–6.
10.1016/S1995-7645(13)60174-1
CAS PubMed Web of Science® Google Scholar
38Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67: 6092–9.
10.1158/0008-5472.CAN-06-4607
CAS PubMed Web of Science® Google Scholar
39Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008; 47: 1223–32.
10.1002/hep.22158
CAS PubMed Web of Science® Google Scholar
40Gao P, Wong CC, Tung EK, et al. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol. 2011; 54: 1177–84.
10.1016/j.jhep.2010.09.023
CAS PubMed Web of Science® Google Scholar
41Jia Y, Liu H, Zhuang Q, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep. 2012; 27: 1865–72.
CAS PubMed Web of Science® Google Scholar
42Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013; 52: 297–303.
10.1002/mc.21864
CAS PubMed Web of Science® Google Scholar
43Shigehara K, Yokomuro S, Ishibashi O, et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS ONE. 2011; 6: e23584.
10.1371/journal.pone.0023584
CAS PubMed Web of Science® Google Scholar
44Cao P, Zhou L, Zhang J, et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013; 35: 720–8.
10.1002/hed.23011
PubMed Web of Science® Google Scholar
45Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97: 853–61.
10.1002/bjs.7000
CAS PubMed Web of Science® Google Scholar
46Wu BL, Xu LY, Du ZP, et al. MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol. 2011; 17: 79–88.
10.3748/wjg.v17.i1.79
CAS PubMed Web of Science® Google Scholar
47Zhu L, Yan W, Rodriguez-Canales J, et al. MicroRNA analysis of microdissected normal squamous esophageal epithelium and tumor cells. Am J Cancer Res. 2011; 1: 574–84.
PubMed Web of Science® Google Scholar
48Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013; 19: 1292–300.
CAS PubMed Web of Science® Google Scholar
49Papaconstantinou IG, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013; 42: 67–71.
10.1097/MPA.0b013e3182592ba7
CAS PubMed Web of Science® Google Scholar
50Yu T, Wang XY, Gong RG, et al. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res. 2009; 28: 64.
10.1186/1756-9966-28-64
CAS PubMed Web of Science® Google Scholar
51Gao L, Ren W, Chang S, et al. Downregulation of miR-145 expression in oral squamous cell carcinomas and its clinical significance. Onkologie. 2013; 36: 194–9.
10.1159/000349956
CAS PubMed Web of Science® Google Scholar
52Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009; 125: 345–52.
10.1002/ijc.24390
CAS PubMed Web of Science® Google Scholar
53Song T, Xia W, Shao N, et al. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010; 11: 905–11.
PubMed Web of Science® Google Scholar
54Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013; 132: 2479–91.
10.1002/ijc.27949
CAS PubMed Web of Science® Google Scholar
55Ratert N, Meyer HA, Jung M, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013; 15: 695–705.
10.1016/j.jmoldx.2013.05.008
CAS PubMed Web of Science® Google Scholar
56Dip N, Reis ST, Srougi M, et al. Expression profile of microrna-145 in urothelial bladder cancer. Int Braz J Urol. 2013; 39: 95–101; discussion 2.
10.1590/S1677-5538.IBJU.2013.01.12
PubMed Web of Science® Google Scholar
57Zaravinos A, Radojicic J, Lambrou GI, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol. 2012; 188: 615–23.
10.1016/j.juro.2012.03.122
CAS PubMed Web of Science® Google Scholar
58Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009; 100: 1002–11.
10.1038/sj.bjc.6604948
CAS PubMed Web of Science® Google Scholar
59Haapa-Paananen S, Chen P, Hellstrom K, et al. Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS ONE. 2013; 8: e60930.
10.1371/journal.pone.0060930
CAS PubMed Web of Science® Google Scholar
60Sand M, Skrygan M, Georgas D, et al. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci. 2012; 68: 119–26.
10.1016/j.jdermsci.2012.09.004
CAS PubMed Web of Science® Google Scholar
61Sand M, Skrygan M, Sand D, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012; 167: 847–55.
10.1111/j.1365-2133.2012.11022.x
CAS PubMed Web of Science® Google Scholar
62Gits CM, van Kuijk PF, Jonkers MB, et al. Microrna expression profiles distinguish liposarcoma subtypes and implicate MIR-145 AND MIR-451 as tumor suppressors. Int J Cancer. 2014; 135: 348–61.
10.1002/ijc.28694
CAS PubMed Web of Science® Google Scholar
63Akao Y, Nakagawa Y, Kitade Y, et al. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007; 98: 1914–20.
10.1111/j.1349-7006.2007.00618.x
CAS PubMed Web of Science® Google Scholar
64Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007; 12: 414–8.
10.1016/j.ccr.2007.10.028
CAS PubMed Web of Science® Google Scholar
65Barlev NA, Sayan BS, Candi E, et al. The microRNA and p53 families join forces against cancer. Cell Death Differ. 2010; 17: 373–5.
10.1038/cdd.2009.73
CAS PubMed Web of Science® Google Scholar
66Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009; 106: 3207–12.
10.1073/pnas.0808042106
CAS PubMed Web of Science® Google Scholar
67Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011; 32: 772–8.
10.1093/carcin/bgr036
CAS PubMed Web of Science® Google Scholar
68Shi M, Du L, Liu D, et al. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol. 2012; 228: 148–57.
10.1002/path.3997
CAS PubMed Web of Science® Google Scholar
69Ren D, Wang M, Guo W, et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. Int J Oncol. 2013; 42: 1473–81.
10.3892/ijo.2013.1825
CAS PubMed Web of Science® Google Scholar
70Spizzo R, Nicoloso MS, Lupini L, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010; 17: 246–54.
10.1038/cdd.2009.117
CAS PubMed Web of Science® Google Scholar
71Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009; 460: 529–33.
10.1038/nature08199
CAS PubMed Web of Science® Google Scholar
72Zhang J, Sun Q, Zhang Z, et al. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013; 32: 61–9.
10.1038/onc.2012.28
CAS PubMed Web of Science® Google Scholar
73Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev. 2003; 13: 6–13.
10.1016/S0959-437X(02)00017-5
CAS PubMed Web of Science® Google Scholar
74Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010; 24: 2754–9.
10.1101/gad.1950610
CAS PubMed Web of Science® Google Scholar
75Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. 2013; 32: 2576–85.
10.1038/onc.2012.266
CAS PubMed Web of Science® Google Scholar
76Mosakhani N, Sarhadi VK, Borze I, et al. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosom Cancer. 2012; 51: 1–9.
10.1002/gcc.20925
CAS PubMed Web of Science® Google Scholar
77Sachdeva M, Liu Q, Cao J, et al. Negative regulation of miR-145 by C/EBP-beta through the Akt pathway in cancer cells. Nucleic Acids Res. 2012; 40: 6683–92.
10.1093/nar/gks324
CAS PubMed Web of Science® Google Scholar
78Gan B, Lim C, Chu G, et al. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010; 18: 472–84.
10.1016/j.ccr.2010.10.019
CAS PubMed Web of Science® Google Scholar
79Schepeler T, Holm A, Halvey P, et al. Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene. 2012; 31: 2750–60.
10.1038/onc.2011.453
CAS PubMed Web of Science® Google Scholar
80Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J Cell Biol. 2012; 197: 201–8.
10.1083/jcb.201110008
CAS PubMed Web of Science® Google Scholar
81Hong S, Noh H, Chen H, et al. Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. Sci Signal. 2013; 6: ra16.
10.1126/scisignal.2003706
CAS PubMed Web of Science® Google Scholar
82Xhemalce B, Robson SC, Kouzarides T. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell. 2012; 151: 278–88.
10.1016/j.cell.2012.08.041
CAS PubMed Web of Science® Google Scholar
83Iio A, Takagi T, Miki K, et al. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. Biochim Biophys Acta. 2013; 1829: 1102–10.
10.1016/j.bbagrm.2013.07.010
CAS PubMed Web of Science® Google Scholar
84Sureban SM, May R, Qu D, et al. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS ONE. 2013; 8: e73940.
10.1371/journal.pone.0073940
CAS PubMed Web of Science® Google Scholar
85Shi B, Sepp-Lorenzino L, Prisco M, et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007; 282: 32582–90.
10.1074/jbc.M702806200
CAS PubMed Web of Science® Google Scholar
86La Rocca G, Badin M, Shi B, et al. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol. 2009; 220: 485–91.
10.1002/jcp.21796
CAS PubMed Web of Science® Google Scholar
87Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011; 8: 125–31.
10.4161/rna.8.1.14259
CAS PubMed Web of Science® Google Scholar
88Zhang J, Guo H, Qian G, et al. MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer. 2010; 9: 211.
10.1186/1476-4598-9-211
CAS PubMed Web of Science® Google Scholar
89Ostenfeld MS, Bramsen JB, Lamy P, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. 2010; 29: 1073–84.
10.1038/onc.2009.395
CAS PubMed Web of Science® Google Scholar
90Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010; 70: 378–87.
10.1158/0008-5472.CAN-09-2021
CAS PubMed Web of Science® Google Scholar
91Fuse M, Nohata N, Kojima S, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011; 38: 1093–101.
CAS PubMed Web of Science® Google Scholar
92Speranza MC, Frattini V, Pisati F, et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012; 3: 723–34.
10.18632/oncotarget.547
PubMed Google Scholar
93Yu CC, Tsai LL, Wang ML, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013; 73: 3425–40.
10.1158/0008-5472.CAN-12-3840
CAS PubMed Web of Science® Google Scholar
94Xu N, Papagiannakopoulos T, Pan G, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009; 137: 647–58.
10.1016/j.cell.2009.02.038
CAS PubMed Web of Science® Google Scholar
95Hu J, Guo H, Li H, et al. MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4. PLoS ONE. 2012; 7: e45965.
10.1371/journal.pone.0045965
CAS PubMed Web of Science® Google Scholar
96Fan L, Wu Q, Xing X, et al. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 2012; 44: 407–14.
10.1093/abbs/gms019
CAS PubMed Web of Science® Google Scholar
97Xu Q, Liu LZ, Qian X, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012; 40: 761–74.
10.1093/nar/gkr730
CAS PubMed Web of Science® Google Scholar
98Zou C, Xu Q, Mao F, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012; 11: 2137–45.
10.4161/cc.20598
CAS PubMed Web of Science® Google Scholar
99Lee CY, Rennie PS, Jia WW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res. 2009; 15: 5126–35.
10.1158/1078-0432.CCR-09-0051
CAS PubMed Web of Science® Google Scholar
100Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 2008; 3: e2557.
10.1371/journal.pone.0002557
CAS PubMed Web of Science® Google Scholar
101Xing AY, Wang B, Shi DB, et al. Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol. 2013; 95: 91–7.
10.1016/j.yexmp.2013.05.003
CAS PubMed Web of Science® Google Scholar
102Law PT, Ching AK, Chan AW, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012; 33: 1134–41.
10.1093/carcin/bgs130
CAS PubMed Web of Science® Google Scholar
103Zhu H, Dougherty U, Robinson V, et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res. 2011; 9: 960–75.
10.1158/1541-7786.MCR-10-0531
CAS PubMed Web of Science® Google Scholar
104Zhong M, Ma X, Sun C, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact. 2010; 184: 431–8.
10.1016/j.cbi.2010.01.025
CAS PubMed Web of Science® Google Scholar
105Noguchi S, Yasui Y, Iwasaki J, et al. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013; 328: 353–61.
10.1016/j.canlet.2012.10.017
CAS PubMed Web of Science® Google Scholar
106Sudbery I, Enright AJ, Fraser AG, et al. Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. BMC Genomics. 2010; 11: 175.
10.1186/1471-2164-11-175
CAS PubMed Web of Science® Google Scholar
107Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010; 103: 256–64.
10.1038/sj.bjc.6605742
CAS PubMed Web of Science® Google Scholar
108Noguchi S, Yamada N, Kumazaki M, et al. socs7, a target gene of microRNA-145, regulates interferon-beta induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis. 2013; 4: e482.
10.1038/cddis.2013.11
CAS PubMed Web of Science® Google Scholar
109Chen Z, Zeng H, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010; 29: 151.
10.1186/1756-9966-29-151
CAS PubMed Web of Science® Google Scholar
110Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002; 419: 729–34.
10.1038/nature01119
CAS PubMed Web of Science® Google Scholar
111Zhang W, Wang Q, Yu M, et al. MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat. 2014; 13: 161–8.
10.7785/tcrt.2012.500367
CAS PubMed Web of Science® Google Scholar
112Kim SJ, Oh JS, Shin JY, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 2011; 155: 427–34.
10.1016/j.jconrel.2011.06.026
CAS PubMed Web of Science® Google Scholar
113Wang F, Xia J, Wang N, et al. miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. Onkologie. 2013; 36: 754–8.
10.1159/000356978
PubMed Web of Science® Google Scholar
114Shao Y, Qu Y, Dang S, et al. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 2013; 13: 51.
10.1186/1475-2867-13-51
CAS PubMed Web of Science® Google Scholar
115Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005; 41: 2462–78.
10.1016/j.ejca.2005.08.013
CAS PubMed Web of Science® Google Scholar
116Zhang J, Guo H, Zhang H, et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011; 117: 86–95.
10.1002/cncr.25522
CAS PubMed Web of Science® Google Scholar
117Hart M, Wach S, Nolte E, et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 2013; 280: 2105–16.
10.1111/febs.12236
CAS PubMed Web of Science® Google Scholar
118Zheng L, Pu J, Qi T, et al. miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. Mol Cancer Res. 2013; 11: 182–93.
10.1158/1541-7786.MCR-12-0534
CAS PubMed Web of Science® Google Scholar
119Kovar H. Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med. 2010; 2: 8.
10.1186/gm129
CAS PubMed Web of Science® Google Scholar
120Ban J, Jug G, Mestdagh P, et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene. 2011; 30: 2173–80.
10.1038/onc.2010.581
CAS PubMed Web of Science® Google Scholar
121Miles GD, Seiler M, Rodriguez L, et al. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012; 5: 164.
10.1186/1756-0500-5-164
CAS PubMed Google Scholar
122Wang S, Bian C, Yang Z, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 2009; 34: 1461–6.
CAS PubMed Web of Science® Google Scholar
123Gregersen LH, Jacobsen AB, Frankel LB, et al. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS ONE. 2010; 5: e8836.
10.1371/journal.pone.0008836
CAS PubMed Web of Science® Google Scholar
124Noh JH, Chang YG, Kim MG, et al. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013; 335: 455–62.
10.1016/j.canlet.2013.03.003
CAS PubMed Web of Science® Google Scholar
125Villadsen SB, Bramsen JB, Ostenfeld MS, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012; 106: 366–74.
10.1038/bjc.2011.520
CAS PubMed Web of Science® Google Scholar
126Tchernitsa O, Kasajima A, Schafer R, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol. 2010; 222: 310–9.
10.1002/path.2759
CAS PubMed Web of Science® Google Scholar
127Leite KR, Tomiyama A, Reis ST, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2013; 31: 796–801.
10.1016/j.urolonc.2011.07.002
CAS PubMed Web of Science® Google Scholar
128Shao Y, Zhang SQ, Quan F, et al. MicroRNA-145 inhibits the proliferation, migration and invasion of the human TCA8113 oral cancer line. Oncol Lett. 2013; 6: 1636–40.
10.3892/ol.2013.1621
CAS PubMed Web of Science® Google Scholar
129Baldus SE, Monig SP, Huxel S, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004; 10: 2790–6.
10.1158/1078-0432.CCR-03-0163
CAS PubMed Web of Science® Google Scholar
130Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 2003; 22: 1324–32.
10.1038/sj.onc.1206291
CAS PubMed Web of Science® Google Scholar
131Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2010; 2: 170–80.
CAS PubMed Web of Science® Google Scholar
132Wu H, Xiao Z, Wang K, et al. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun. 2013; 441: 693–700.
10.1016/j.bbrc.2013.10.053
CAS PubMed Web of Science® Google Scholar
133Dynoodt P, Speeckaert R, De Wever O, et al. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol. 2013; 42: 1443–51.
10.3892/ijo.2013.1823
CAS PubMed Web of Science® Google Scholar
134Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010; 102: 883–91.
10.1038/sj.bjc.6605570
CAS PubMed Web of Science® Google Scholar
135Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010; 127: 2804–14.
10.1002/ijc.25284
CAS PubMed Web of Science® Google Scholar
136Liu R, Liao J, Yang M, et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS ONE. 2012; 7: e33987.
10.1371/journal.pone.0033987
CAS PubMed Web of Science® Google Scholar
137Gotte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010; 29: 6569–80.
10.1038/onc.2010.386
CAS PubMed Web of Science® Google Scholar
138Noguchi S, Mori T, Hoshino Y, et al. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci. 2012; 74: 1–8.
10.1292/jvms.11-0264
CAS PubMed Web of Science® Google Scholar
139Chiyomaru T, Tatarano S, Kawakami K, et al. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate. 2011; doi: 10.1002/pros.21372.
10.1002/pros.21372
PubMed Web of Science® Google Scholar
140Tikhmyanova N, Golemis EA. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS ONE. 2011; 6: e22102.
10.1371/journal.pone.0022102
CAS PubMed Web of Science® Google Scholar
141O'Neill GM, Seo S, Serebriiskii IG, et al. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007; 67: 8975–9.
10.1158/0008-5472.CAN-07-1328
CAS PubMed Web of Science® Google Scholar
142Guo W, Ren D, Chen X, et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem. 2013; 114: 1606–15.
10.1002/jcb.24502
CAS PubMed Web of Science® Google Scholar
143Lu R, Ji Z, Li X, et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014; 140: 387–97.
10.1007/s00432-013-1577-z
CAS PubMed Web of Science® Google Scholar
144Gao P, Xing AY, Zhou GY, et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013; 32: 491–501.
10.1038/onc.2012.61
CAS PubMed Web of Science® Google Scholar
145Rani SB, Rathod SS, Karthik S, et al. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol. 2013; 15: 1302–16.
10.1093/neuonc/not090
CAS PubMed Web of Science® Google Scholar
146Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007; 98: 621–8.
10.1111/j.1349-7006.2007.00434.x
CAS PubMed Web of Science® Google Scholar
147Doberstein K, Steinmeyer N, Hartmetz AK, et al. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia. 2013; 15: 218–30.
10.1593/neo.121222
CAS PubMed Web of Science® Google Scholar
148Lu Y, Chopp M, Zheng X, et al. MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep. 2013; 29: 67–72.
10.3892/or.2012.2084
PubMed Web of Science® Google Scholar
149Lee HK, Bier A, Cazacu S, et al. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS ONE. 2013; 8: e54652.
10.1371/journal.pone.0054652
CAS PubMed Web of Science® Google Scholar
150Yamada N, Noguchi S, Mori T, et al. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett. 2013; 335: 332–42.
10.1016/j.canlet.2013.02.060
CAS PubMed Web of Science® Google Scholar
151Wang Z, Zhang X, Yang Z, et al. MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochem Biophys Res Commun. 2012; 427: 444–9.
10.1016/j.bbrc.2012.06.123
CAS PubMed Web of Science® Google Scholar
152Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009; 9: 374.
10.1186/1471-2407-9-374
CAS PubMed Web of Science® Google Scholar
153Koo S, Martin GS, Schulz KJ, et al. Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer. 2012; 12: 143.
10.1186/1471-2407-12-143
CAS PubMed Google Scholar
154Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275–84.
10.1038/nrc1590
CAS PubMed Web of Science® Google Scholar
155Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012; 31: 285–93.
10.1007/s10555-012-9345-0
Web of Science® Google Scholar
156Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663–76.
10.1016/j.cell.2006.07.024
CAS PubMed Web of Science® Google Scholar
157Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861–72.
10.1016/j.cell.2007.11.019
CAS PubMed Web of Science® Google Scholar
158Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318: 1917–20.
10.1126/science.1151526
CAS PubMed Web of Science® Google Scholar
159Fang X, Yoon JG, Li L, et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics. 2011; 12: 11.
10.1186/1471-2164-12-11
CAS PubMed Web of Science® Google Scholar
160Wu Y, Liu S, Xin H, et al. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer. 2011; 117: 3989–98.
10.1002/cncr.25944
CAS PubMed Web of Science® Google Scholar
161Yin R, Zhang S, Wu Y, et al. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 2011; 25: 1747–54.
CAS PubMed Web of Science® Google Scholar
162Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci USA. 2012; 109: 14470–5.
10.1073/pnas.1212811109
CAS PubMed Web of Science® Google Scholar
163Huang S, Guo W, Tang Y, et al. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012; 28: 1831–7.
10.3892/or.2012.2015
CAS PubMed Web of Science® Google Scholar
164Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1: 149–53.
10.1038/nm0295-149
CAS PubMed Web of Science® Google Scholar
165Yin Y, Yan ZP, Lu NN, et al. Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim Biophys Acta. 2013; 1829: 239–47.
10.1016/j.bbagrm.2012.11.006
CAS PubMed Web of Science® Google Scholar
166Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012; 106: 1526–34.
10.1038/bjc.2012.109
CAS PubMed Web of Science® Google Scholar
167Chinnathambi S, Wiechert S, Tomanek-Chalkley A, et al. Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145. J Dermatol. 2012; 39: 617–24.
10.1111/j.1346-8138.2012.01553.x
CAS PubMed Web of Science® Google Scholar
168Bockmeyer CL, Christgen M, Muller M, et al. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat. 2011; 130: 735–45.
10.1007/s10549-010-1303-3
CAS PubMed Web of Science® Google Scholar
169Wach S, Nolte E, Szczyrba J, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012; 130: 611–21.
10.1002/ijc.26064
CAS PubMed Web of Science® Google Scholar
170Li X, Luo F, Li Q, et al. Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. Oncol Rep. 2011; 26: 1431–9.
PubMed Web of Science® Google Scholar
171Fischer L, Hummel M, Korfel A, et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol. 2011; 13: 1090–8.
10.1093/neuonc/nor107
CAS PubMed Web of Science® Google Scholar
172Wach S, Nolte E, Theil A, et al. MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer. 2013; 109: 714–22.
10.1038/bjc.2013.313
CAS PubMed Web of Science® Google Scholar
173Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer. 2013; 23: 673–9.
10.1097/IGC.0b013e31828c166d
PubMed Web of Science® Google Scholar
174Zhu W, Qin W, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009; 2: 89.
10.1186/1756-0500-2-89
CAS PubMed Web of Science® Google Scholar
175Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013; 34: 163–9.
10.1155/2013/259454
CAS PubMed Web of Science® Google Scholar
176Ng EK, Li R, Shin VY, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS ONE. 2013; 8: e53141.
10.1371/journal.pone.0053141
CAS PubMed Web of Science® Google Scholar
177Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012; 72: 1469–77.
10.1002/pros.22499
CAS PubMed Web of Science® Google Scholar
178Tang D, Shen Y, Wang M, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013; 22: 540–8.
10.1097/CEJ.0b013e32835f3be9
CAS PubMed Web of Science® Google Scholar
179Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012; 41: 1871–8.
10.3892/ijo.2012.1622
CAS PubMed Web of Science® Google Scholar
180Li JM, Zhao RH, Li ST, et al. Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med J. 2012; 33: 24–9.
PubMed Web of Science® Google Scholar
181Campayo M, Navarro A, Vinolas N, et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J. 2013; 41: 1172–8.
10.1183/09031936.00048712
CAS PubMed Web of Science® Google Scholar
182Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012; 33: 1046–54.
10.1093/carcin/bgs100
CAS PubMed Web of Science® Google Scholar
183Huang L, Lin JX, Yu YH, et al. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS ONE. 2012; 7: e33762.
10.1371/journal.pone.0033762
CAS PubMed Web of Science® Google Scholar
184Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007; 72: 397–402.
10.1159/000113489
CAS PubMed Web of Science® Google Scholar
185Drebber U, Lay M, Wedemeyer I, et al. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol. 2011; 39: 409–15.
PubMed Web of Science® Google Scholar
186Zhang J, Zhang K, Bi M, et al. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2014; 25: 346–52.
10.1097/CAD.0000000000000049
CAS PubMed Web of Science® Google Scholar
187Wang CJ, Zhou ZG, Wang L, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers. 2009; 26: 27–34.
10.1155/2009/921907
CAS PubMed Web of Science® Google Scholar
188Schee K, Boye K, Abrahamsen TW, et al. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012; 12: 505.
10.1186/1471-2407-12-505
CAS PubMed Web of Science® Google Scholar
189Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010; 18: 181–7.
10.1038/mt.2009.207
CAS PubMed Web of Science® Google Scholar
190Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 2008; 105: 3903–8.
10.1073/pnas.0712321105
CAS PubMed Web of Science® Google Scholar
191Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005–17.
10.1016/j.cell.2009.04.021
CAS PubMed Web of Science® Google Scholar
192Ibrahim AF, Weirauch U, Thomas M, et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71: 5214–24.
10.1158/0008-5472.CAN-10-4645
CAS PubMed Web of Science® Google Scholar
193Lee HK, Finniss S, Cazacu S, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013; 4: 346–61.
10.18632/oncotarget.868
PubMed Web of Science® Google Scholar
194Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009; 77: 12–21.
10.1159/000218166
CAS PubMed Web of Science® Google Scholar
195Peng W, Hu J, Zhu XD, et al. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol. 2014; 35: 2983–8.
10.1007/s13277-013-1383-x
CAS PubMed Web of Science® Google Scholar
196Ikemura K, Yamamoto M, Miyazaki S, et al. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol. 2013; 83: 399–405.
10.1124/mol.112.081844
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume18, Issue10

October 2014

Pages 1913-1926

MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways

Abstract

Introduction

MiR-145 Biogenesis

Down-regulation of miR-145 in cancer

The functions and pathways involving miR-145 targets

MiR-145 in tumour growth inhibition

MiR-145 in cancer invasion and metastasis

MiR-145 in the differentiation of cancer stem cells

MiR-145 in angiogenesis

MiR-145 and cancer-associated virus

MiR-145 in cancer diagnosis and prognosis

MiR-145 in cancer therapy

Conclusions and future directions

Acknowledgements

Conflicts of interest

References

Citing Literature

Figures

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways

Abstract

Introduction

MiR-145 Biogenesis

Down-regulation of miR-145 in cancer

The functions and pathways involving miR-145 targets

MiR-145 in tumour growth inhibition

MiR-145 in cancer invasion and metastasis

MiR-145 in the differentiation of cancer stem cells

MiR-145 in angiogenesis

MiR-145 and cancer-associated virus

MiR-145 in cancer diagnosis and prognosis

MiR-145 in cancer therapy

Conclusions and future directions

Acknowledgements

Conflicts of interest

References

Citing Literature

Figures

References

Related

Information